Question 1

What are the potential side effects of MS-275?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma clinical trial (NCT00185302). Contact the study team or your healthcare provider for specific answers.

Question 2

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma clinical trial (NCT00185302). Contact the study team or your healthcare provider for specific answers.

Question 3

What will the treatment schedule look like for me?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma clinical trial (NCT00185302). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my progress be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma clinical trial (NCT00185302). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any risks I should be aware of before participating?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma clinical trial (NCT00185302). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects or my condition worsens?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Melanoma clinical trial (NCT00185302). Contact the study team or your healthcare provider for specific answers.

What this study is about